ADMAADMA Biologics, Inc.

$4B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+77.3% YoY

Gross Profit

$17M27.8% margin

Operating Income

-$473,000-0.8% margin

Net Income

-$6M-10.6% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$7M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$343M

Total Liabilities

$196M

Stockholders' Equity

$147M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$34M	+77.3%
Gross Profit	$17M	$8M	+114.8%
Operating Income	-$473,000	-$9M	+94.8%
Net Income	-$6M	-$14M	+53.7%

Revenue Segments

ADMA BioManufacturing Segment

$60M99%

Plasma Collection Centers Segment

$326,3461%

Corporate Segment

$35,7090%

Geographic Segments

United States

$57M100%

ADMA Q2 2023 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena